Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Treatment Patterns in Metastatic Prostate Cancer

24 de janeiro de 2018 atualizado por: Bayer

Treatment Patterns, Mortality, Healthcare Resource Utilization, and Costs in Patients With Prostate Cancer With Bone Metastases: A Retrospective Database Analysis .

This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary objective). The study is descriptive in nature and is meant to provide a greater understanding of the patterns of therapy observed in real-world clinical practice (in the absence of clear guideline recommendations with regards to treatment sequencing), to contribute to a greater understanding of the major cost drivers (thus better-informing payers), and to examine real-world mortality in such patients.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Observacional

Inscrição (Real)

565

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

45 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Método de amostragem

Amostra Não Probabilística

População do estudo

Part 1 - Assessment of treatment patterns, healthcare resource utilization, and costs The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date.

Part 2 - Assessment of mortality The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date.

Descrição

Inclusion Criteria:

- Subjects with at least one claim with a primary diagnosis of prostate cancer (International Classification of Diseases(ICD) Clinical Modification (CM)185.xx )and any of the below on same day or after the prostate cancer claim:

  • At least one inpatient claim with a primary or secondary diagnosis indicating bone metastases (ICD 9 CM 198.5 or Healthcare Common Procedure Coding System (HCPCS) code for a treatment indicative of bone metastases OR
  • At least two outpatient claims with a primary or secondary diagnosis indicating bone metastases (ICD 9 CM 198.5 or HCPCS code for a treatment indicative of bone metastases, with a minimum of 30 days between claims.

Exclusion Criteria:

  • Subjects with a diagnosis of a cancer other than prostate cancer - defined as the presence of one inpatient or two outpatient claims with a primary or secondary diagnosis of malignant neoplasms (ICD-9-CM 140.xx-171.xx, 174.xx-184.xx,186.xx-195.xx,200.xx-209.3x, 230.xx-239.xx) - in the 12-month pre-index period.
  • Subjects with any claim for a primary or secondary diagnosis indicating bone metastases (ICD-9-CM 198.5) or any treatment indicative of bone metastases in the 12-month pre-index period.
  • Patients who had a SRE in the 12-month pre-index period.
  • Subjects without continuous enrollment for at least 12 months before the index date.
  • Subjects without continuous eligibility for at least 6 months after the index date.
  • Subjects that are female.
  • Subjects that have negative costs.
  • Subjects that are less than 45 years of age on the index date.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Treatment patterns, healthcare resource utilization and costs
Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
Medicamento: Xofigo (Radium 223 dichloride,BAY88-8223)
Retrospective claims analysis. Descriptive analyses of treatment patterns.
Mortality
Part 2 - Assessment of mortality. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no SREs in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before the index date. Unlike in Part 1, there will be no required minimum follow-up time after the index date (in order to assess mortality).
Medicamento: Xofigo (Radium 223 dichloride,BAY88-8223)
Retrospective claims analysis. Descriptive analyses of treatment patterns.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Distribution of treatment types among lines of therapy
Prazo: Up to 6 months
Possible Treatment Types: Sipuleucel-T, Abiraterone, Enzalutamide, Docetaxel, Cabazitaxel, Radium-223, Anti-Androgens, All other chemotherapy(oral and injectables), Radiation therapy
Up to 6 months
Time to treatment (days)
Prazo: Up to 6 months
Up to 6 months
Duration of treatment (days)
Prazo: Up to 6 months
Up to 6 months
Number of patients on each drug or drug combination
Prazo: Up to 6 months
Drug: Sipuleucel-T, Abiraterone, Enzalutamide, Docetaxel, Cabazitaxel, Radium-223, Anti-Androgens, All other chemotherapy(oral and injectables), Radiation therapy
Up to 6 months
Number of inpatient visits per patient
Prazo: Upto 6 month post index period
Upto 6 month post index period
Length of hospital stay (days) among those with an inpatient visit
Prazo: Upto 6 month post index period
Upto 6 month post index period
Number of outpatient visits per patient
Prazo: Upto 6 month post index period
Upto 6 month post index period
Number of emergency room (ER) visits per patient
Prazo: Upto 6 month post index period
Upto 6 month post index period
Number of physician office visits per patient
Prazo: Upto 6 month post index period
Upto 6 month post index period
Number of medication prescriptions per patient
Prazo: Upto 6 month post index period
Upto 6 month post index period
Number of patients by provider type
Prazo: Upto 6 month post index period
Upto 6 month post index period
Number of claims per patient
Prazo: Upto 6 month post index period
Upto 6 month post index period
Total costs of healthcare
Prazo: Upto 6 month post index period
Upto 6 month post index period
Medical costs of healthcare
Prazo: Upto 6 month post index period
Upto 6 month post index period
Pharmacy costs of healthcare
Prazo: Upto 6 month post index period
Upto 6 month post index period
Per-patient-per-month (PPPM)) costs of healthcare
Prazo: Upto 6 month post index period
Upto 6 month post index period
Mortality rate
Prazo: Up to 6 months
Up to 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Opioid/analgesic use among lines of therapy(Y/N)
Prazo: Up to 6 months
Opioid and analgesics use among lines of therapy (e.g. 1st, 2nd, 3rd)
Up to 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Bayer

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de outubro de 2016

Conclusão Primária (Real)

19 de janeiro de 2017

Conclusão do estudo (Real)

19 de janeiro de 2017

Datas de inscrição no estudo

Enviado pela primeira vez

16 de março de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

31 de março de 2016

Primeira postagem (Estimativa)

6 de abril de 2016

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de janeiro de 2018

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de janeiro de 2018

Última verificação

1 de janeiro de 2018

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 18695

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Xofigo (Radium 223 dichloride,BAY88-8223)

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Spain

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

3
Se inscrever